Download PDF
Neuropediatrics 2022; 53(05): 351-357
DOI: 10.1055/a-1863-1862
Original Article

Seroprevalence of MOG and AQP4 Antibodies and Outcomes in an Indian Cohort of Pediatric Acquired Demyelinating Syndromes

Naveen Sankhyan
1   Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Amit Rawat
2   Pediatric Allergy and Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Sameer Vyas 
3   Section of Neuroimaging and Interventional Radiology, Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Jitendra Kumar Sahu
1   Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Chandana Bhagwat
1   Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Priyanka Madaan
1   Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Lokesh Saini 
1   Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Arushi Gahlot Saini 
1   Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Renu Suthar
1   Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Jaspreet Sukhija
4   Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Murlidharan Jayashree
5   Pediatric Critical Care Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
› Author Affiliations Funding The study was supported by a grant from Postgraduate Institute of Medical Education and Research, Chandigarh (No.71/2-Edu-16/ 4774; Nov 11, 2017).
› Further Information
    Permissions and Reprints

Abstract

This study aimed to determine the seropositivity of myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) and aquaporin-4 antibodies (AQP4-Ab) and outcomes in children with acquired demyelinating syndromes (ADSs). Children (6 months–15 years) with suspected ADS were enrolled and tested for MOG-Ab and AQP4-Ab prospectively over 18 months at a tertiary care hospital in North India. Children with proven nonimmune-mediated neurological disorders were enrolled as controls. Of 79 children with suspected ADS, 66 were enrolled. Among the enrolled children with ADS, acute demyelinating encephalomyelitis (ADEM) (25) was the most common first clinical event followed by optic neuritis (ON) (20) and transverse myelitis (TM) (19; one child had ON and TM simultaneously [neuromyelitis optica spectrum disorders [NMOSDs]]), while two children had clinically isolated syndrome (CIS) apart from ON and TM. Fourteen (21.2%, confidence interval [CI] 11.3–31.1) tested positive for one antibody (12 [18.1%; 95% CI 10.5–25.5%] for MOG-Ab and 2 [3%; 95% CI 0–7.2%] for AQP4-Ab). None of the 62 controls tested positive for any antibody. The final diagnosis in those with the monophasic ADS was ADEM (21), ON (13), TM (16), and other CIS (1) while that in children with recurrent events was multiphasic disseminated encephalomyelitis (MDEM) (2), NMOSD (3), ADEM-ON (4), recurrent ON (4), and MS (2). Among those with the first event, 4/51 (7.8%; 95% CI 0.5–15.2%) were MOG-Ab positive and 2 AQP4-Ab positive, whereas 8/15 (53.3% [95% CI 28.1–78.6%]) with recurrent events (MDEM [2], ADEM-ON [4], recurrent ON [1], and recurrent TM [1]) were MOG-Ab positive. Hence, MOG-Abs are the most common antibodies detected in one in five children with pediatric ADS, especially in relapsing disease. AQP4-Abs are rare in children with ADS.

Keywords

demyelination - children - MOG - AQP-4

Author Contributions

N.S.: Conceptualization of the study, facilitated the data collection, patient management, statistical analysis, and critical review of the manuscript, and review of literature. A.R.: Conceptualization of the study, facilitated the data collection, and autoantibody analysis. S.V.: Conceptualization of the study and interpretation of radiological data. J.K.S.: Conceptualization of the study, and facilitated data collection and patient management. C.B., L.S., A.G.S., R.S., J.M.: Facilitated data collection and patient management. P.M.: Facilitated data collection, patient management, reviewed the literature, and prepared the initial draft of the manuscript. J.S.: Ophthalmological testing of patients and its interpretation, and patient management. All the authors contributed to the manuscript.




Publication History

Received: 22 February 2022

Accepted: 24 May 2022

Accepted Manuscript online:
26 May 2022

Article published online:
24 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Neuteboom R, Wilbur C, Van Pelt D, Rodriguez M, Yeh A. The spectrum of inflammatory acquired demyelinating syndromes in children. Semin Pediatr Neurol 2017; 24 (03) 189-200
    CrossrefPubMedGoogle Scholar
  • 2 Madaan P, Bhagwat C, Sankhyan N. Acute disseminated encephalomyelitis. Indian J Pract Pediatr 2020; 22 (01) 21
    PubMedGoogle Scholar
  • 3 Ketelslegers IA, Van Pelt DE, Bryde S. et al. Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. Mult Scler 2015; 21 (12) 1513-1520
    CrossrefPubMedGoogle Scholar
  • 4 Lennon VA, Wingerchuk DM, Kryzer TJ. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364 (9451): 2106-2112
    CrossrefPubMedGoogle Scholar
  • 5 Krupp LB, Tardieu M, Amato MP. et al; International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19 (10) 1261-1267
    CrossrefPubMedGoogle Scholar
  • 6 Banwell B, Kennedy J, Sadovnick D. et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009; 72 (03) 232-239
    CrossrefPubMedGoogle Scholar
  • 7 Absoud M, Lim MJ, Chong WK. et al; UK and Ireland Childhood CNS Inflammatory Demyelination Working Group. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler 2013; 19 (01) 76-86
    CrossrefPubMedGoogle Scholar
  • 8 McKeon A, Lennon VA, Lotze T. et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008; 71 (02) 93-100
    CrossrefPubMedGoogle Scholar
  • 9 Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202 (04) 473-477
    CrossrefPubMedGoogle Scholar
  • 10 Tillema JM, McKeon A. The spectrum of neuromyelitis optica (NMO) in childhood. J Child Neurol 2012; 27 (11) 1437-1447
    CrossrefPubMedGoogle Scholar
  • 11 Banwell B, Tenembaum S, Lennon VA. et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008; 70 (05) 344-352
    CrossrefPubMedGoogle Scholar
  • 12 Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics 2008; 122 (05) e1039-e1047
    CrossrefPubMedGoogle Scholar
  • 13 Absoud M, Lim MJ, Appleton R. et al. Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features. J Neurol Neurosurg Psychiatry 2015; 86 (04) 470-472
    CrossrefPubMedGoogle Scholar
  • 14 Fernandez-Carbonell C, Vargas-Lowy D, Musallam A. et al. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler 2016; 22 (02) 174-184
    CrossrefPubMedGoogle Scholar
  • 15 Waters P, Fadda G, Woodhall M. et al. Canadian Pediatric Demyelinating Disease Network. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol 2020; 77 (01) 82-93
    CrossrefPubMedGoogle Scholar
  • 16 Armangue T, Olivé-Cirera G, Martínez-Hernandez E. et al; Spanish Pediatric anti-MOG Study Group. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol 2020; 19 (03) 234-246
    CrossrefPubMedGoogle Scholar
  • 17 Gulati S, Chakrabarty B, Kumar A, Jain P, Patel H, Saini L. Acquired demyelinating disorders of central nervous system: a pediatric cohort. Ann Indian Acad Neurol 2015; 18 (Suppl. 01) S48-S55
    CrossrefPubMedGoogle Scholar
  • 18 Suthar R, Sankhyan N, Sahu JK, Khandelwal NK, Singhi S, Singhi P. Acute transverse myelitis in childhood: a single centre experience from North India. Eur J Paediatr Neurol 2016; 20 (03) 352-360
    CrossrefPubMedGoogle Scholar
  • 19 Iype M, Kunju PAM, Saradakutty G, Anish TS, Sreedharan M, Ahamed SM. Short term outcome of ADEM: results from a retrospective cohort study from South India. Mult Scler Relat Disord 2017; 18: 128-134
    CrossrefPubMedGoogle Scholar
  • 20 Netravathi M, Bollampalli HK, Bhat MD. et al. Clinical, neuroimaging and therapeutic response in AQP4-positive NMO patients from India. Mult Scler Relat Disord 2019; 30: 85-93
    CrossrefPubMedGoogle Scholar
  • 21 Papais-Alvarenga RM, Neri VC, de Araújo E Araújo ACR. et al. Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: an ethnicity influence?. Mult Scler Relat Disord 2018; 25: 87-94
    CrossrefPubMedGoogle Scholar
  • 22 Thompson AJ, Banwell BL, Barkhof F. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17 (02) 162-173
    CrossrefPubMedGoogle Scholar
  • 23 Wingerchuk DM, Banwell B, Bennett JL. et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85 (02) 177-189
    CrossrefPubMedGoogle Scholar
  • 24 de Mol CL, Wong Y, van Pelt ED. et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler 2020; 26 (07) 806-814
    CrossrefPubMedGoogle Scholar
  • 25 Boesen MS, Jensen PEH, Born AP. et al. Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008–2018: a nationwide, population-based cohort study. Mult Scler Relat Disord 2019; 33: 162-167
    CrossrefPubMedGoogle Scholar
  • 26 Hennes EM, Baumann M, Schanda K. et al; BIOMARKER Study Group. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 2017; 89 (09) 900-908
    CrossrefPubMedGoogle Scholar
  • 27 Duignan S, Wright S, Rossor T. et al. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol 2018; 60 (09) 958-962
    CrossrefPubMedGoogle Scholar
  • 28 Saini L, Dhawan SR, Madaan P. et al. Infection-associated opsoclonus: a retrospective case record analysis and review of literature. J Child Neurol 2020; 35 (07) 480-484
    CrossrefPubMedGoogle Scholar